MUMBAI (TIP): Indian generic drugmaker Ranbaxy Laboratories said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid programme. The company, which has agreed to be acquired by rival Sun Pharmaceutical Industries, said it had received a civil investigative demand (CID) from the US Department of Justice (DOJ) and that it would fully cooperate with the investigation. “The CID is a request for documents and information, and is not an allegation of wrongdoing or demand for compensation,” the company said in a statement. Last year, Ranbaxy pleaded guilty to felony charges related to drug safety.
Related Articles
Georgia judge dismisses two more charges against Trump in election case
ATLANTA, GA (TIP): An Atlanta-area judge has thrown out two more charges against former president Donald Trump and a third against several of his allies in a sprawling election interference case accusing them of criminally […]
Valentine’s Day: Time of the year to celebrate love
Valentine’s Day (or Saint Valentine’s Day) is observed on February 14 each year. Today Valentine’s Day is celebrated in many countries around the world, mostly in the West, although it remains a working day in […]
Liu Proposes People’s Budget
Time to Stop the Music and End the Annual Budget Dance;Offers Plan to Fund Education, Public Safety, and Restore ‘The NYC Dream’ NEW YORK, NY (TIP): City Comptroller John C. Liu , April 9, unveiled […]
Be the first to comment